Precipio (PRPO) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	9 Months Ended
	Sep. 30, 2023	Nov. 09, 2023
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-36439
Entity Registrant Name	PRECIPIO, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	91-1789357
Entity Address, Address Line One	4 Science Park
Entity Address, City or Town	New Haven
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06511
City Area Code	203
Local Phone Number	787-7888
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	PRPO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,420,125
Entity Central Index Key	0001043961
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash		$ 1,562	$ 3,445
Accounts receivable, net		1,483	1,036
Inventories		636	708
Other current assets		628	521
Total current assets		4,309	5,710
PROPERTY AND EQUIPMENT, NET		738	877
OTHER ASSETS:
Finance lease right-of-use assets, net		194	257
Operating lease right-of-use assets, net		668	763
Intangibles, net		13,056	13,768
Other assets		88	129
Total assets		19,053	21,504
CURRENT LIABILITIES:
Current maturities of long-term debt, less debt issuance costs		334	255
Current maturities of finance lease liabilities		143	162
Current maturities of operating lease liabilities		222	199
Accounts payable		2,513	2,042
Accrued expenses		2,213	1,584
Deferred revenue		29	119
Total current liabilities		5,454	4,361
LONG TERM LIABILITIES:
Long-term debt, less current maturities and debt issuance costs		113	134
Finance lease liabilities, less current maturities		25	68
Operating lease liabilities, less current maturities		459	574
Total liabilities		6,051	5,137
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' EQUITY:
Preferred stock - $0.01 par value, 15,000,000 shares authorized at September 30, 2023 and December 31, 2022, 47 shares issued and outstanding at September 30, 2023 and December 31, 2022, liquidation preference of $33 at September 30, 2023
Common stock, $0.01 par value, 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, 1,380,555 and 1,141,013 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	[1]	14	11
Additional paid-in capital	[1]	111,998	108,588
Accumulated deficit		(99,075)	(92,297)
Total Precipio, Inc. stockholders' equity		12,937	16,302
Noncontrolling interest in joint venture		65	65
Total stockholders' equity		13,002	16,367
Total liabilities and stockholders' equity		$ 19,053	$ 21,504
[1] The common stock and additional paid-in capital for all periods presented reflect the one-for- twenty reverse stock split, which was effected on September 21, 2023.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Sep. 30, 2023 USD ($) $ / shares shares
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000
Preferred stock, shares issued (in shares)	47
Preferred stock, shares outstanding (in shares)	47
Preferred stock, liquidation preference | $	$ 33
Common stock, par value | $ / shares	$ 0.01
Common stock, shares authorized (in shares)	150,000,000
Common stock, shares issued (in shares)	1,380,555
Common stock, shares outstanding (in shares)	1,380,555

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue, net of contractual allowances and adjustments		$ 4,569	$ 2,295	$ 11,043	$ 7,268
Adjustment for allowance for doubtful accounts		(51)	(80)	(175)	(247)
Net sales		4,518	2,215	10,868	7,021
Total cost of sales		2,633	1,779	6,863	5,109
Gross profit		1,885	436	4,005	1,912
OPERATING EXPENSES:
Operating expenses		3,333	3,665	10,771	12,383
OPERATING LOSS		(1,448)	(3,229)	(6,766)	(10,471)
OTHER (EXPENSE) INCOME:
Interest expense, net		(7)	(6)	(12)	(6)
Warrant revaluation			59		578
Gain on settlement of liability			3		4
Total other (expense) income		(7)	56	(12)	576
LOSS BEFORE INCOME TAXES		(1,455)	(3,173)	(6,778)	(9,895)
NET LOSS		(1,455)	(3,173)	(6,778)	(9,895)
Less: Net income attributable to noncontrolling interest in joint venture			(6)		(18)
NET LOSS ATTRIBUTABLE TO PRECIPIO, INC. COMMON STOCKHOLDERS		$ (1,455)	$ (3,179)	$ (6,778)	$ (9,913)
LOSS PER COMMON SHARE, BASIC	[1]	$ (1.04)	$ (2.79)	$ (5.39)	$ (8.72)
LOSS PER COMMON SHARE, DILUTED		$ (1.04)	$ (2.79)	$ (5.39)	$ (8.72)
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC	[1]	1,394,596	1,138,345	1,258,633	1,136,414
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, DILUTED		1,394,596	1,138,345	1,258,633	1,136,414
Service revenue, net
Revenue, net of contractual allowances and adjustments		$ 3,738	$ 2,060	$ 8,574	$ 6,291
Adjustment for allowance for doubtful accounts		(51)	(80)	(175)	(247)
Net sales		3,687	1,980	8,399	6,044
Total cost of sales		2,401	1,512	6,050	4,414
Other revenue
Revenue, net of contractual allowances and adjustments		831	235	2,469	977
Net sales		831	235	2,469	977
Total cost of sales		$ 232	$ 267	$ 813	$ 695
[1] Net loss per share and the number of shares used in the per share calculations for all periods presented reflect the one-for- twenty reverse stock split, which was effected on September 21, 2023.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)	Sep. 21, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Reverse stock split	0.05

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - USD ($) $ in Thousands		Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	[1]	Accumulated Deficit [Member]	Total Precipio, Inc. [Member]	Noncontrolling Interest in Joint Venture [Member]	Total
Balance at beginning of period at Dec. 31, 2021			$ 11	[1]	$ 104,647		$ (80,094)	$ 24,564	$ 40	$ 24,604
Balance at beginning of period (in shares) at Dec. 31, 2021		47	1,135,422	[1]
Increase (Decrease) in Stockholders' Equity
Net loss							(9,913)	(9,913)	18	(9,895)
Issuance of common stock in connection with at the market offering, net of issuance costs					129			129		129
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)	[1]		4,251
Proceeds upon issuance of common stock from exercise of warrants					11			11		11
Proceeds upon issuance of common stock from exercise of warrants (in shares)	[1]		1,340
Stock-based compensation					3,405			3,405		3,405
Balance at end of period at Sep. 30, 2022			$ 11	[1]	108,192		(90,007)	18,196	58	18,254
Balance at end of period (in shares) at Sep. 30, 2022		47	1,141,013	[1]
Balance at beginning of period at Jun. 30, 2022			$ 11	[1]	107,330		(86,828)	20,513	52	20,565
Balance at beginning of period (in shares) at Jun. 30, 2022		47	1,135,435	[1]
Increase (Decrease) in Stockholders' Equity
Net loss							(3,179)	(3,179)	6	(3,173)
Issuance of common stock in connection with purchase agreements, net of issuance costs					129			129		129
Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares)	[1]		4,251
Proceeds upon issuance of common stock from exercise of warrants					11			11		11
Proceeds upon issuance of common stock from exercise of warrants (in shares)	[1]		1,327
Stock-based compensation					722			722		722
Balance at end of period at Sep. 30, 2022			$ 11	[1]	108,192		(90,007)	18,196	58	18,254
Balance at end of period (in shares) at Sep. 30, 2022		47	1,141,013	[1]
Balance at beginning of period at Dec. 31, 2022			$ 11	[1]	108,588		(92,297)	16,302	65	16,367
Balance at beginning of period (in shares) at Dec. 31, 2022		47	1,141,013	[1]
Increase (Decrease) in Stockholders' Equity
Net loss							(6,778)	(6,778)		(6,778)
Payment of fractional common shares in conjunction with the reverse stock split.	[1]		(52)
Issuance of common stock in connection restricted stock awards					16			16		16
Issuance of common stock in connection restricted stock awards (in shares)	[1]		2,492
Issuance of common stock in connection with purchase agreements, net of issuance costs			$ 2	[1]	1,758			1,760		1,760
Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares)	[1]		206,250
Issuance of common stock in connection with at the market offering, net of issuance costs			$ 1	[1]	484			485		485
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)	[1]		30,852
Stock-based compensation					1,152			1,152		1,152
Balance at end of period at Sep. 30, 2023			$ 14	[1]	111,998		(99,075)	12,937	65	13,002
Balance at end of period (in shares) at Sep. 30, 2023		47	1,380,555	[1]
Balance at beginning of period at Jun. 30, 2023			$ 14	[1]	111,632		(97,620)	14,026	65	14,091
Balance at beginning of period (in shares) at Jun. 30, 2023		47	1,378,115	[1]
Increase (Decrease) in Stockholders' Equity
Net loss							(1,455)	(1,455)		(1,455)
Payment of fractional common shares in conjunction with the reverse stock split.	[1]		(52)
Issuance of common stock in connection restricted stock awards					16			16		16
Issuance of common stock in connection restricted stock awards (in shares)	[1]		2,492
Stock-based compensation					350			350		350
Balance at end of period at Sep. 30, 2023			$ 14	[1]	$ 111,998		$ (99,075)	$ 12,937	$ 65	$ 13,002
Balance at end of period (in shares) at Sep. 30, 2023		47	1,380,555	[1]
[1] The common stock and additional paid-in capital for all periods presented reflect the one-for- twenty reverse stock split, which was effected on September 21, 2023.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)	Sep. 21, 2023
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]
Reverse stock split	0.05

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,778)	$ (9,895)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	931	910
Amortization of operating lease right-of-use asset	153	139
Amortization of finance lease right-of-use asset	63	99
Amortization of deferred financing costs, debt discounts and debt premiums	2	3
Gain on settlement of liability		(4)
Stock-based compensation	1,168	3,405
Provision for losses on doubtful accounts	175	245
Warrant revaluation		(578)
Changes in operating assets and liabilities:
Accounts receivable	(622)	(503)
Inventories	72	(99)
Other assets	306	341
Accounts payable	468	235
Operating lease liabilities	(150)	(136)
Deferred revenue	(90)	(5)
Accrued expenses	629	(378)
Net cash used in operating activities	(3,673)	(6,221)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(77)	(225)
Net cash used in investing activities	(77)	(225)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on finance lease obligations	(62)	(124)
Issuance of common stock, net of issuance costs	2,245	129
Proceeds from exercise of warrants		11
Principal payments on long-term debt	(316)	(94)
Net cash flows provided by (used in) financing activities	1,867	(78)
NET CHANGE IN CASH	(1,883)	(6,524)
CASH AT BEGINNING OF PERIOD	3,445	11,668
CASH AT END OF PERIOD	1,562	5,144
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the period for interest	29	32
SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY
Purchases of equipment financed through accounts payable	3	34
Prepaid insurance financed with loan	372	413
Operating lease right-of-use assets obtained in exchange for operating lease obligations	$ 58	$ 92

BUSINESS DESCRIPTION

BUSINESS DESCRIPTION	9 Months Ended
	Sep. 30, 2023
BUSINESS DESCRIPTION [Abstract]
BUSINESS DESCRIPTION	1. BUSINESS DESCRIPTION Business Description. Precipio, Inc., and its subsidiaries, (collectively, “we”, “us”, “our”, the “Company” or “Precipio”) is a healthcare solutions company focused on cancer diagnostics. The Company’s business mission is to address the pervasive problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. Misdiagnoses originate from outdated commercial diagnostic cancer testing technologies, lack of subspecialized expertise, and sub-optimal laboratory processes that are needed in today’s diagnostic cancer testing in order to provide accurate, rapid, and resource-effective results to treat patients. Industry studies estimate 1 in 5 blood-cancer patients are misdiagnosed. As cancer diagnostic testing has evolved from cellular to molecular (genes and exons), laboratory testing has become extremely complex, requiring even greater diagnostic precision, attention to process and a more appropriate evaluation of the abundance of genetic data to effectively gather, consider, analyze and present information for the physician for patient treatment. Precipio believes cancer diagnostics requires a holistic approach to improve the quality of diagnostic data and achieve more accurate interpretations of the patient situation, with the intent to reduce misdiagnoses. By delivering products, reagents and services that improve the accuracy and efficiency of diagnostics, leading to fewer misdiagnoses, we believe patient outcomes can be improved through the selection of appropriate therapeutic options. Furthermore, we believe that better patient outcomes will have a positive impact on healthcare expenses as misdiagnoses are reduced. Better Diagnostic Results – Better Patient Outcome – Lower Healthcare Expenditures. ​ To deliver its strategy, the Company has structured its organization to develop diagnostic products. Laboratory and R&D facilities located in New Haven, Connecticut and Omaha, Nebraska house teams that collaborate on the development of new products and services. The Company operates CLIA laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment. ​ Our Products Division commercial team generates direct sales as well as works with our key distributors. Global healthcare distributors, such as ThermoFisher and McKesson, have partnered with us to form the backbone of the Company’s go-to-market strategy and enable us to access laboratories around the country that can benefit from using our diagnostic products. ​ Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market the Company’s robust pipeline of innovative solutions designed to address the root causes of misdiagnoses. Joint Venture. The Company has determined that it holds a variable interest in a joint venture formed in April 2020 (the “Joint Venture”) and is the primary beneficiary of the variable interest entity (“VIE”). See Note 2 - Summary of Significant Accounting Policies for further discussion regarding consolidation of variable interest entities. Going Concern. The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the nine months ended September 30, 2023, the Company had a net loss of $6.8 million and net cash used in operating activities of $3.7 million. As of September 30, 2023, the Company had an accumulated deficit of $99.1 million and a negative working capital of $1.1 million. The Company’s ability to continue as a going concern over the next twelve months from the date of issuance of these condensed consolidated financial statements in this Quarterly Report on Form 10-Q is dependent upon a combination of achieving its business plan, including generating additional revenue and avoiding potential business disruption due to the macroeconomic environment and geopolitical instability, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan: ● On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to $5.8 million, to or through AGP, as sales agent (the “AGP 2023 Sales Agreement”). The sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the “2023 Registration Statement”) on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023. As of the date the condensed consolidated financial statements were issued, we have received less than $1 thousand in gross proceeds through the AGP 2023 Sales Agreement from the sale of 25 shares of common stock. The Company has approximately $3.8 million available for future sales pursuant to the AGP 2023 Sales Agreement . See Note 7 Stockholders’ Equity, AGP 2023 Sales Agreement, for further discussion. ● On June 8, 2023, the Company entered into a securities purchase agreement pursuant to which it received $2.0 million in gross proceeds through the sale of 206,250 shares of common stock and warrants to purchase shares of our common stock. Issuance costs were approximately $0.2 million and the Company intends to use the net proceeds for working capital and general corporate purposes. See Note 7 Stockholders’ Equity, Registered Direct Offering, for further discussion. ​ Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these condensed consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance of this Quarterly Report Form 10-Q. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty. Nasdaq Compliance. On October 28, 2022, we received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying us that for the past 30 consecutive business days, the closing bid price per share of our common stock was below $1.00, the minimum bid price requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). On April 27, 2023, Nasdaq notified us that we were eligible for an extension to comply with the Bid Price Rule until October 23, 2023, by which date we must have regained compliance with the Bid Price Rule for at least ten consecutive business days along with compliance of other Nasdaq listing rules. On September 21, 2023 we filed a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, pursuant to which we effected a 1-for- 20 , and our common stock began trading on a split-adjusted basis on the Nasdaq Capital Market at the market open on September 22 . On October 6, 2023, we received notification from Nasdaq that for ten consecutive business days, the closing bid price of our common stock was at least $1.00 per share, and accordingly, the Company regained compliance with the Bid Price Rule, and that the matter is now closed.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to the Reverse Stock Split , unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. The condensed consolidated financial statements include the accounts of Precipio and its wholly owned subsidiaries, and the Joint Venture which is a VIE in which we are the primary beneficiary. Refer to the section titled “Consolidation of Variable Interest Entities” for further information related to our accounting for the Joint Venture. All intercompany balances have been eliminated in consolidation. Reclassification. Certain reclassifications were made to the statements of cash flows related to splitting accruals and deferred revenue to separate lines in order to conform to the 2023 presentation. These reclassifications had no effect on previously reported retained earnings, net income, total assets or liabilities, or cash flows used in operating activities. Recently Adopted Accounting Pronouncements. In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments guidance on January 1, 2023. The adoption of this standard was not material to our condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The provisions in this Update are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company does not expect to early adopt this ASU. The Company is currently assessing the potential impact that the adoption of this ASU will have on its condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 705,976 and 226,434 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2023 and 2022, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2023 2022 Stock options 234,213 184,936 Warrants 465,888 35,623 Preferred stock 5,875 5,875 Total 705,976 226,434 ​ Consolidation of Variable Interest Entities. We evaluate any entity in which we are involved to determine if the entity is a VIE and if so, whether we hold a variable interest and are the primary beneficiary. We consolidate VIEs that are subject to assessment when we are deemed to be the primary beneficiary of the VIE. The process for determining whether we are the primary beneficiary of the VIE is to conclude whether we are a party to the VIE holding a variable interest that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE, and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. ​ We have determined that we hold a variable interest in the Joint Venture, have the power to make significant operational decisions on behalf of the VIE and also have the obligation to absorb the majority of the losses from the VIE. As such we have also determined that we are the primary beneficiary of the VIE. The following table presents information about the carrying value of the assets and liabilities of the Joint Venture which we consolidate and which are included on our condensed consolidated balance sheets. Intercompany balances are eliminated in consolidation and not reflected in the following table. ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 219 ​ $ 335 Total assets ​ $ 219 ​ $ 335 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 17 ​ $ 50 Total liabilities ​ $ 17 ​ $ 50 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 65 Equity attributable to Precipio, Inc. ​ $ 127 ​ $ 127 ​

LONG-TERM DEBT

LONG-TERM DEBT	9 Months Ended
	Sep. 30, 2023
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	3. LONG-TERM DEBT Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ September 30, 2023 December 31, 2022 Connecticut Department of Economic and Community Development (DECD) ​ $ 154 ​ $ 176 DECD debt issuance costs ​ (13) ​ (15) Financed insurance loan ​ 306 ​ 228 Total long-term debt ​ 447 ​ 389 Current portion of long-term debt ​ (334) ​ (255) Long-term debt, net of current maturities ​ $ 113 ​ $ 134 ​ Department of Economic and Community Development. On January 8, 2018, the Company entered into an agreement with the Connecticut Department of Economic and Community Development (“DECD”) by which the Company received a loan of $300,000 secured by substantially all of the Company’s assets (the “DECD 2018 Loan”). The DECD 2018 Loan is a ten-year loan due on December 31, 2027 and includes interest paid monthly at 3.25%. The maturity date of the DECD 2018 Loan was extended to May 31, 2028 and the modification did not have a material impact on the Company’s cash flows. Amortization of the debt issuance costs were less than $1 thousand for the three months ended September 30, 2023 and 2022, respectively, and $2 thousand and $3 thousand for the nine months ended September 30, 2023 and 2022, respectively. Financed Insurance Loan. The Company finances certain of its insurance premiums (the “Financed Insurance Loans”). In July 2023, the Company financed $0.4 million with a 9.99% interest rate and is obligated to make payments on a monthly basis through June 2024. In July 2022, the Company financed $0.4 million with a 5.99% interest rate and made payments on a monthly basis through June 2023. As of September 30, 2023 and December 31, 2022, the Financed Insurance Loan’s outstanding balance of $0.3 million and $0.2 million, respectively, was included in current maturities of long-term debt in the Company’s condensed consolidated balance sheets. A corresponding prepaid asset was included in other current assets.

ACCRUED EXPENSES OTHER CURRENT

ACCRUED EXPENSES OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2023
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
ACCRUED EXPENSES OTHER CURRENT LIABILITIES	4 Accrued expenses at September 30, 2023 and December 31, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Accrued expenses ​ $ 1,212 ​ $ 983 Accrued compensation ​ 846 ​ 491 Accrued franchise, property and sales and use taxes ​ ​ 136 ​ ​ 91 Accrued interest ​ 19 ​ 19 ​ ​ $ 2,213 ​ $ 1,584 ​ The Company recorded certain settled reductions in accrued expenses and accounts payable as gains which are included in gain on settlement of liability, net in the condensed consolidated statements of operations. During the three months ended September 30, 2023 and 2022, zero and $3 thousand, respectively, were recorded as a gain on settlement of liability. During the nine months ended September 30, 2023 and 2022, zero and $4 thousand, respectively, were recorded as a gain on settlement of liability.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	5 The Company is involved in legal proceedings related to matters, which are incidental to its business. Also, the Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. See below for a discussion on these matters. PURCHASE COMMITMENTS The Company has entered into purchase commitments for reagents from suppliers. These agreements started in 2011 and run through 2025. The Company and the suppliers will true up the amounts on an annual basis. The future minimum purchase commitments under these and other purchase agreements are approximately $0.7 million and $1.3 million at September 30, 2023 and December 31, 2022, respectively. LITIGATIONS CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owed approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of less than $0.1 million has been recorded and is reflected in accounts payable within the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022. LEGAL AND REGULATORY ENVIRONMENT The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2023
LEASES [Abstract]
LEASES	6 The Company leases administrative facilities and laboratory equipment through operating lease agreements. In addition, we rent various equipment used in our diagnostic lab and in our administrative offices through finance lease arrangements. Our operating leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common area or other maintenance costs). The facility leases include one or more options to renew, from 1 to 5 years or more. The exercise of lease renewal options is typically at our sole discretion, therefore, the renewals to extend the lease terms are not included in our right-of-use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and, when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Operating leases result in the recognition of ROU assets and lease liabilities on the balance sheet. ROU assets represent our right to use the leased asset for the lease term and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The primary leases we enter into with initial terms of 12 months or less are for equipment. The Company also recognizes ROU assets from finance leases in connection with its HemeScreen Reagent Rental (“HSRR”) program. For certain customers in the HSRR program, the Company leases diagnostic testing equipment and then subleases the equipment to the customer. Finance lease ROU assets and finance lease liabilities are recognized at the lease commencement date, and at the sublease commencement date the finance lease ROU asset is derecognized and is recorded as cost of sales in the condensed consolidated statements of operations. There were no derecognized finance lease ROU assets for the three and nine months ended September 30, 2023 and 2022, respectively. Where Precipio is the lessor, customers lease diagnostic testing equipment from the Company with the transfer of ownership to the customer at the end of the lease term at no additional cost. For these contracts, the Company accounts for the arrangements as sales-type leases. The lease asset for sales-type leases is the net investment in leased asset, which is recorded once the finance lease ROU asset is derecognized and a related gain or loss is noted. The net investment in leased assets was $0.1 million as of September 30, 2023 and December 31, 2022, respectively, and is included in other current assets and other assets in our condensed consolidated balance sheets. The balance sheet presentation of our operating and finance leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Condensed Consolidated Balance Sheet ​ September 30, 2023 ​ December 31, 2022 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 668 ​ $ 763 Finance lease right-of-use assets, net (1) ​ ​ 194 ​ ​ 257 Total lease assets ​ $ 862 ​ $ 1,020 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 222 ​ $ 199 Current maturities of finance lease liabilities ​ ​ 143 ​ ​ 162 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 459 ​ ​ 574 Finance lease liabilities, less current maturities ​ ​ 25 ​ ​ 68 Total lease liabilities ​ $ 849 ​ $ 1,003 (1) As of September 30, 2023 and December 31, 2022, finance lease right-of-use assets included $3 thousand and $13 thousand, respectively, of assets related to finance leases associated with the HSRR program. ​ As of September 30, 2023, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ September 30, ​ ​ September 30, ​ ​ September 30, ​ ​ ​ 2023 ​ ​ 2023 ​ ​ 2023 2023 (remaining) ​ $ 68 ​ $ 22 ​ $ 90 2024 ​ 258 ​ 80 ​ 338 2025 ​ 224 ​ 65 ​ 289 2026 ​ 214 ​ ​ 26 ​ 240 Total lease obligations ​ 764 ​ 193 ​ 957 Less: Amount representing interest ​ (83) ​ (25) ​ (108) Present value of net minimum lease obligations ​ 681 ​ 168 ​ 849 Less, current portion ​ (222) ​ (143) ​ (365) Long term portion ​ $ 459 ​ $ 25 ​ $ 484 ​ Other information as of September 30, 2023 and December 31, 2022 is as follows: ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2023 ​ 2022 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 3.0 ​ 3.7 Finance leases 2.3 ​ 2.8 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 10.54% ​ 10.31% ​ During the nine months ended September 30, 2023 and 2022, operating cash flows from operating leases was $0.2 million and $0.1 million, respectively, and operating lease ROU assets obtained in exchange for operating lease liabilities was $0.1 million, respectively. Operating Lease Costs Operating lease costs were approximately $0.1 million during the three months ended September 30, 2023 and 2022, respectively, and $0.2 million for the nine months ended September 30, 2023 and 2022, respectively. These costs are primarily related to long-term operating leases for the Company’s facilities and laboratory equipment. Short-term and variable lease costs were less than $0.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. Finance Lease Costs Finance lease amortization and interest expenses are included in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022. The balances within these accounts are less than $0.1 million, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2023
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	7 Common Stock. Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance. On December 20, 2018, the Company’s shareholders approved the proposal to authorize the Company’s Board of Directors to, in its discretion, amend the Company’s Third Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet implemented this increase. During the three and nine months ended September 30, 2023, the Company issued zero shares of its common stock, respectively, in connection with the exercise of warrants. During the three and nine months ended September 30, 2022, the Company 1,327 and 1,340 shares of its common stock, respectively, in connection with the exercise of 1,327 and 1,340 warrants, respectively. The warrant exercises during the three and nine months ended September 30, 2022 resulted in net cash proceeds to the Company of $11 thousand, respectively. At The Market Offering Agreement ​ AGP Sales Agreement ​ On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (“AGP”), pursuant to which the Company was permitted to offer and sell its common stock, par value $0.01 per share (the “Common Stock”) (the “Shares”), having aggregate sales proceeds of up to $22.0 million. Shares can be sold either directly to or through AGP as a sales agent (the “AGP Sales Agreement”), from time to time, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the Shares (the “2021 ATM Offering”). The Company is limited in the number of shares it can sell in the 2021 ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company’s public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP Sales Agreement. ​ The sale of our shares of Common Stock to or through AGP, will be made pursuant to the registration statement (the “Registration Statement”) on Form S-3 (File No. 333-237445), which was declared effective by the Securities and Exchange Commission (the “SEC”) on April 13, 2020, for an aggregate offering price of up to $50.0 million. Under the AGP Sales Agreement, Shares were permitted to be sold by any method permitted by law deemed to be an “at the market offering.” AGP will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the AGP Sales Agreement, AGP was required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. AGP is not under any obligation to purchase any of the Shares on a principal basis pursuant to the AGP Sales Agreement, except as otherwise agreed by AGP and the Company in writing and expressly set forth in a placement notice. AGP’s obligations to sell the Shares under the AGP Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the AGP Sales Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Company’s capital raising needs. The Company agreed to pay AGP a cash fee of 3.0% of the aggregate gross proceeds from the sale of the Shares on the Company’s behalf pursuant to the AGP Sales Agreement. The AGP Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has provided AGP with customary indemnification and contribution rights. The Company also agreed to reimburse AGP for certain specified expenses, including the expenses of counsel to AGP. The offering of the Shares pursuant to the AGP Sales Agreement terminated upon the expiration of the Company’s Registration Statement on Form S-3 (File No. 333-237445). ​ During the three and nine months ended September 30, 2023, we received net proceeds of zero and $0.5 million from the sale of zero and 30,827 . ​ As of the date of issuance of this Quarterly Report on Form 10-Q, we have received an aggregate of $15.6 million in net proceeds, after issuance costs of approximately $0.5 million, from the sale of 260,128 shares of common stock pursuant to the AGP Sales Agreement. ​ AGP 2023 Sales Agreement ​ On April 14, 2023, the Company entered into the AGP 2023 Sales Agreement, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the shares of Common Stock. AGP will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares of Common Stock pursuant to the AGP 2023 Sales Agreement. ​ The sale of our shares of Common Stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the 2023 Registration Statement on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023, for an aggregate offering price of up to $5.8 million. ​ During the three and nine months ended September 30, 2023, we received net proceeds of less than $1 thousand, respectively, from the sale of 25 shares of common stock pursuant to the AGP 2023 Sales Agreement. As a result of sales already made through the AGP 2023 Sales Agreement and the Registered Direct Offering, mentioned below, the Company has approximately $3.8 million available for future sales pursuant to the AGP 2023 Sales Agreement. ​ Registered Direct Offering ​ On June 8, 2023, the Company, entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), an aggregate of: (i) 206,250 shares (the “Shares”) of its common stock, $0.01 par value (the “Common Stock”), at a price of $9.00 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,972 shares of Common Stock, at a price of $8.98 per Pre-Funded Warrant. The Company reviewed the provisions of the Pre-Funded Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The Pre-Funded Warrants are immediately exercisable, have an exercise price of $0.02 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. As of September 30, 2023, no Pre-Funded Warrants have been exercised. In a concurrent private placement (the “Private Placement” and together with the Registered Direct Offering, the “Offering”), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, for no additional consideration, warrants (the “RDO Common Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”) to purchase up to 444,444 shares of Common Stock. The Company reviewed the provisions of the RDO Common Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of $12.60 per share, and will expire December 12, 2028. The fair value of the RDO Common Warrants of approximately $3.5 million at the date of issuance was estimated using the Black-Scholes model which used the following inputs: term of 5 years; risk free rate of 3.89%; volatility of 143%; and share price of $9.00 per share based on the trading price of the Company’s common stock. The Company allocated $1.3 million of the issuance proceeds to the RDO Common Warrants based on the relative fair value of the RDO Common Warrants, Common Stock and Pre-Funded Warrants issued in the Offering. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Registered Direct Offering resulted in gross proceeds to the Company of approximately $2.0 million. The net proceeds to the Company from the Registered Direct Offering are approximately $1.8 million, excluding any proceeds that may be received upon the cash exercise of the RDO Common Warrants, after deducting the financial advisor’s fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Registered Direct Offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments and others. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions. Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the “Lock-Up Agreements”), agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, during the 90-day period following the closing of the Registered Direct Offering. The Purchase Agreement also requires the Company to use commercially reasonable efforts to file a registration statement with the SEC to register the resale by the Purchasers of the shares of Common Stock issuable upon exercise of the RDO Common Warrants within thirty (30) days of the date of the Purchase Agreement. The Company filed this registration statement on Form S-1 (File No. 333-273172), which was declared effective by the SEC on July 19, 2023. On June 7, 2023, the Company also entered into a financial advisory agreement (the “Financial Advisor Agreement”) with A.G.P./Alliance Global Partners (the “Financial Advisor”). Pursuant to the terms of the Financial Advisor Agreement, the Financial Advisor agreed to use its reasonable best efforts to arrange for the sale of the Securities. The Company paid the Financial Advisor a cash fee of $140,000 generated from the sale of the Shares and Pre-Funded Warrants. The Financial Advisor Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Financial Advisor, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties, and termination provisions. ​ Pursuant to the Purchase Agreement, the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of common stock or securities exercisable or convertible into shares of common stock or to file any registration statement or amendment or supplement thereto for a period of ninety (90) days following the closing of the Offering and that (ii) it will not enter into a variable rate transaction for a period of one hundred eighty (180) days following the closing of the Offering. The Registered Direct Offering was made pursuant to the 2023 Registration Statement, as supplemented by a prospectus supplement dated June 9, 2023. There is $3.8 million of remaining availability under the 2023 Registration Statement. ​ Preferred Stock. The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. Series B Preferred Stock. The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (“Series B Preferred Stock”) with the State of Delaware, which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of $1 thousand per share and a par value of $0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering consisting of the Company’s Series B Preferred Stock and warrants. The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. There were no conversions of Series B Preferred Stock during the three and nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company had 6,900 shares of Series B Preferred Stock designated and issued and 47 shares of Series B Preferred Stock outstanding. Based on the stated value of $1 thousand per share and a conversion price of $8.00 per share, the outstanding shares of Series B Preferred Stock at September 30, 2023 were convertible into 5,875 shares of common stock. Common Stock Warrants. The following represents a summary of the warrants outstanding as of September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Underlying Exercise ​ ​ Issue Year ​ Expiration ​ Shares ​ Price Warrants ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) ​ 2018 ​ November 2023 ​ 3,789 ​ $ 108.00 (2) ​ 2018 ​ December 2023 ​ 2,564 ​ $ 108.00 (3) ​ 2019 ​ April 2024 ​ 7,374 ​ $ 108.00 (4) ​ 2019 ​ May 2024 ​ 7,717 ​ $ 191.20 (5) ​ 2023 ​ None ​ 15,972 ​ $ 0.02 (6) ​ 2023 ​ December 2028 ​ 444,444 ​ $ 12.60 ​ 481,860 ​ (1)(2)(3) (4) (5)(6) ​ There were 1,327 and 1,340 w exercised during the three and nine months ended September 30, 2022 for proceeds to the Company of $11 thousand, respectively. During the three and nine months ended September 30, 2022, the intrinsic value of the w exercised was $20 thousand, respectively. During the three and nine months ended September 30, 2023, 5,593 and 13,012 warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2018. Pre -Funded Warrants RDO Common Warrants

FAIR VALUE

FAIR VALUE	9 Months Ended
	Sep. 30, 2023
FAIR VALUE [Abstract]
FAIR VALUE	8 FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated statements of operations. Bridge Note Warrant Liabilities During 2018 and 2019, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the “Bridge Note Warrant Liabilities”). The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. As of September 30, 2023, Bridge Note Warrant Liabilities outstanding were the result of convertible note issuances on various dates in 2018 and 2019. The assumptions used in the valuation of the Bridge Note Warrant Liabilities include the following ranges: remaining life to maturity of 0.25 to 0.62 years; volatility rate of 69% to 85%; and risk-free rate of 5.53% to 5.55%. As of December 31, 2022, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 1.4 years; volatility rate of 69% to 77%; and risk free rate of 4.42 to 4.76%. During the three and nine months ended September 30, 2023, the changes in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were less than $1 thousand, respectively. The changes during the three and nine months ended September 30, 2022 were comprised of the following: ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ Bridge Note ​ Warrant Liabilities ​ Beginning balance at July 1 $ 87 ​ Total gains: ​ Revaluation recognized in earnings ​ (59) ​ Balance at September 30 $ 28 ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ Bridge Note ​ Warrant Liabilities Beginning balance at January 1 $ 606 Total gains: Revaluation recognized in earnings ​ (578) Balance at September 30 $ 28 ​

EQUITY INCENTIVE PLAN

EQUITY INCENTIVE PLAN	9 Months Ended
	Sep. 30, 2023
EQUITY INCENTIVE PLAN [Abstract]
EQUITY INCENTIVE PLAN	9 The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the “2017 Plan”) which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 249,693 at September 30, 2023, of which 12,926 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lessor number of shares determined by the Company’s Board of Directors or Compensation Committee. During the nine months ended September 30, 2023, the shares authorized for issuance increased by 57,051 shares. Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the nine months ended September 30, 2023, the Company granted stock options to purchase up to 58,530 shares of common stock at a weighted average exercise price of $12.12 per share. These awards have vesting periods of up to four years and had a weighted average grant date fair value of $11.60. The fair value calculation of options granted during the nine months ended September 30, 2023 used the following assumptions: risk free interest rate of 3.66% to 4.05%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 146% to 162% based on historical volatility of the Company’s common stock over a time that is consistent with the expected life of the option. The following table summarizes stock option activity under our plans during the nine months ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2023 184,067 ​ $ 56.75 Granted 58,530 ​ 12.12 Forfeited (8,384) ​ 24.12 Outstanding at September 30, 2023 234,213 ​ $ 46.77 Exercisable at September 30, 2023 141,908 ​ $ 57.93 ​ As of September 30, 2023, there were 210,096 options that were vested or expected to vest with aggregate intrinsic value of zero and a remaining weighted average contractual life of 7.8 years. Restricted Stock Awards. Restricted stock awards are subject to vesting restrictions. If a grantee’s service with the Company is terminated prior to vesting of the restricted stock, all unvested shares shall be forfeited and returned to the Company. Upon vesting, the restricted stock award shall no longer be deemed restricted. During the three and nine months ended September 30, 2023, the Company granted 2,492 restricted stock awards to directors of the Company. The awards vested immediately and had a weighted average grant date fair value of $5.90. As of September 30, 2023, there were 2,492 and zero restricted stock awards that were vested and unvested, respectively. There were no restricted stock awards granted during the three and nine months ended September 30, 2022, respectively. Stock Compensation. For the three and nine months ended September 30, 2023, we recorded non-cash stock-based compensation expense for all stock awards of $0.4 million and $1.2 million, respectively, within operating expense in the accompanying statements of operations. Stock compensation expense for the three and nine months ended September 30, 2023, includes approximately $16,000, respectively, of expense related to restricted stock awards. For the three and nine months ended September 30, 2022, we recorded non-cash stock-based compensation expense for all stock awards of $0.7 million and $3.4 million, respectively, within operating expense in the accompanying statements of operations. As of September 30, 2023, the unrecognized compensation expense related to unvested stock awards was $2.5 million, which is expected to be recognized over a weighted-average period of 2.1 years.

SALES SERVICE REVENUE, NET AND

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	9 Months Ended
	Sep. 30, 2023
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	10. SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE ASC Topic 606, “Revenue from contracts with customers” The Company follows the guidance of ASC 606 for the recognition of revenue from contracts with customers to transfer goods and services. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model: ​ Step 1: Identification of the contract with the customer. Sub-steps include determining the customer in a contract, initial contract identification and determining if multiple contracts should be combined and accounted for as a single transaction. Step 2: Identify the performance obligation in the contract. Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct. Step 3: Determine the transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer. Step 4: Allocate transaction price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. Step 5: Satisfaction of performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and when the customer obtains control of the asset upon which time the Company recognizes revenue. ​ Nature of Contracts and Customers The Company’s contracts and related performance obligations are similar for its customers and the sales process for all customers starts upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research. Payment terms for the services provided are 30 days, unless separately negotiated. ​ Diagnostic testing ​ Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient’s laboratory report, per the contract. ​ Clinical research grants ​ Control of the clinical research services are transferred to the customer over time. The Company will recognize revenue utilizing the “effort based” method, measuring its progress toward complete satisfaction of the performance obligation. ​ Biomarker testing and clinical project services ​ Control of the biomarker testing and clinical project services are transferred to the customer over time. The Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results. ​ The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs. Reagents and other diagnostic products Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. These revenues include revenues from reagent sets for our HSRR program and other product sales and are included in other revenue in our condensed consolidated statements of operations. Disaggregation of Revenues by Transaction Type We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Service revenue, net for the three and nine months ended September 30, 2023 and 2022 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, (dollars in thousands) ​ Diagnostic Testing ​ 2023 2022 Medicaid ​ $ 10 ​ $ 12 Medicare ​ 1,691 ​ 936 Self-pay ​ 39 ​ 109 Third party payers ​ 1,998 ​ 1,003 Service revenue, net ​ $ 3,738 ​ $ 2,060 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, (dollars in thousands) ​ Diagnostic Testing ​ 2023 2022 Medicaid ​ $ 22 ​ $ 39 Medicare ​ 3,736 ​ 2,986 Self-pay ​ 155 ​ 206 Third party payers ​ 4,661 ​ 3,060 Service revenue, net ​ $ 8,574 ​ $ 6,291 ​ Revenue from the Medicare and Medicaid programs account for a portion of the Company’s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from the following types of transactions: diagnostic testing (“Diagnostic”), revenues from the Company’s ICP technology and bio-pharma projects encompassing genetic diagnostics (collectively “Biomarker”), revenues from clinical research grants from state and federal research programs and diagnostic product sales, including revenues from equipment leases and reagent sales associated with our HSRR program. Deferred revenue Deferred revenue, or unearned revenue, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer. As the product or service is delivered over time, the Company recognizes the appropriate amount of revenue from deferred revenue. For the periods ended September 30, 2023 and December 31, 2022, the deferred revenue was less than $0.1 million and $0.1 million, respectively. Contractual Allowances and Adjustments We are reimbursed by payers for services we provide. Payments for services covered by payers average less than billed charges. We monitor revenue and receivables from payers and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payers. Accordingly, the total revenue and receivables reported in our condensed consolidated financial statements are recorded at the amounts expected to be received from these payers. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts . The following table presents our revenues initially recognized for each associated payer class during the three and nine months ended September 30, 2023 and 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 10 ​ $ 12 ​ $ — ​ $ — ​ $ 10 ​ $ 12 Medicare ​ 1,693 ​ 936 ​ (2) ​ — ​ 1,691 ​ 936 Self-pay ​ 39 ​ 109 ​ — ​ — ​ 39 ​ 109 Third party payers ​ 6,956 ​ 3,486 ​ (4,958) ​ (2,483) ​ 1,998 ​ 1,003 ​ ​ 8,698 ​ 4,543 ​ (4,960) ​ (2,483) ​ 3,738 ​ 2,060 Other ​ 831 ​ 235 ​ — ​ — ​ 831 ​ 235 ​ ​ $ 9,529 ​ $ 4,778 ​ $ (4,960) ​ $ (2,483) ​ $ 4,569 ​ $ 2,295 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 22 ​ $ 39 ​ $ — ​ $ — ​ $ 22 ​ $ 39 Medicare ​ 3,738 ​ 2,986 ​ (2) ​ — ​ 3,736 ​ 2,986 Self-pay ​ 155 ​ 206 ​ — ​ — ​ 155 ​ 206 Third party payers ​ 16,233 ​ 10,664 ​ (11,572) ​ (7,604) ​ 4,661 ​ 3,060 ​ ​ 20,148 ​ 13,895 ​ (11,574) ​ (7,604) ​ 8,574 ​ 6,291 Other ​ 2,469 ​ 977 ​ — ​ — ​ 2,469 ​ 977 ​ ​ $ 22,617 ​ $ 14,872 ​ $ (11,574) ​ $ (7,604) ​ $ 11,043 ​ $ 7,268 ​ Allowance for Doubtful Accounts The Company provides for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing net sales to the extent it expects to collect that amount. Reference is made to FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts. The change in the allowance for doubtful accounts is directly related to the increase in patient service revenues. The following table presents our reported revenues net of the collection allowance and adjustments for the three and nine months ended September 30, 2023 and 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 10 ​ $ 12 ​ $ (4) ​ $ (6) ​ $ 6 ​ $ 6 Medicare ​ 1,691 ​ 936 ​ (20) ​ (24) ​ 1,671 ​ 912 Self-pay ​ 39 ​ 109 ​ (3) ​ — ​ 36 ​ 109 Third party payers ​ 1,998 ​ 1,003 ​ (24) ​ (50) ​ 1,974 ​ 953 ​ ​ 3,738 ​ 2,060 ​ (51) ​ (80) ​ 3,687 ​ 1,980 Other ​ 831 ​ 235 ​ — ​ — ​ 831 ​ 235 ​ ​ $ 4,569 ​ $ 2,295 ​ $ (51) ​ $ (80) ​ $ 4,518 ​ $ 2,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 22 ​ $ 39 ​ $ (10) ​ $ (19) ​ $ 12 ​ $ 20 Medicare ​ 3,736 ​ 2,986 ​ (43) ​ (75) ​ 3,693 ​ 2,911 Self-pay ​ 155 ​ 206 ​ (15) ​ — ​ 140 ​ 206 Third party payers ​ 4,661 ​ 3,060 ​ (107) ​ (153) ​ 4,554 ​ 2,907 ​ ​ 8,574 ​ 6,291 ​ (175) ​ (247) ​ 8,399 ​ 6,044 Other ​ 2,469 ​ 977 ​ — ​ — ​ 2,469 ​ 977 ​ ​ $ 11,043 ​ $ 7,268 ​ $ (175) ​ $ (247) ​ $ 10,868 ​ $ 7,021 ​ Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the condensed consolidated statements of operations. Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations. Accounts Receivable The Company has provided an allowance for potential credit losses, which has been determined based on management’s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements. The following summarizes the mix of receivables outstanding related to payer categories: ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Medicaid ​ $ 26 ​ $ 34 Medicare ​ 1,671 ​ 1,124 Self-pay ​ 258 ​ 291 Third party payers ​ 1,495 ​ 1,888 Contract diagnostic services and other ​ 562 ​ 53 ​ ​ $ 4,012 ​ $ 3,390 Less allowance for doubtful accounts ​ (2,529) ​ (2,354) Accounts receivable, net ​ $ 1,483 ​ $ 1,036 ​ The following table presents the roll-forward of the allowance for doubtful accounts for the nine months ended September 30, 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Doubtful (dollars in thousands) ​ ​ ​ ​ Accounts Balance, January 1, 2023 ​ ​ $ (2,354) Collection Allowance: ​ ​ Medicaid ​ $ (10) ​ Medicare ​ (43) ​ Self-pay ​ ​ (15) ​ ​ ​ Third party payers ​ (107) ​ ​ ​ (175) ​ Bad debt expense ​ $ — ​ Total charges ​ ​ (175) Balance, September 30, 2023 ​ ​ $ (2,529) ​ Customer Revenue and Accounts Receivable Concentration Our customers are oncologists, hospitals, reference laboratories, physician-office laboratories, and pharma and biotech companies. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Three Months Ended ​ ​ Nine Months Ended ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ ​ September 30, ​ December 31, ​ ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ 13 % * ​ ​ 14 % * ​ ​ 25 % * ​ Customer B ​ 12 % * ​ ​ * ​ * ​ ​ 11 % * ​ Customer C ​ * ​ * ​ ​ * ​ * ​ ​ * ​ 12 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS The Company has evaluated events and transactions subsequent to September 30, 2023 through the date of this Quarterly Report on Form 10-Q, and there are no other events to report other than what has been disclosed in the condensed consolidated financial statements. ​ ​

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation	Basis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to the Reverse Stock Split , unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. The condensed consolidated financial statements include the accounts of Precipio and its wholly owned subsidiaries, and the Joint Venture which is a VIE in which we are the primary beneficiary. Refer to the section titled “Consolidation of Variable Interest Entities” for further information related to our accounting for the Joint Venture. All intercompany balances have been eliminated in consolidation.
Reclassification	Reclassification. Certain reclassifications were made to the statements of cash flows related to splitting accruals and deferred revenue to separate lines in order to conform to the 2023 presentation. These reclassifications had no effect on previously reported retained earnings, net income, total assets or liabilities, or cash flows used in operating activities.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements. In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments guidance on January 1, 2023. The adoption of this standard was not material to our condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The provisions in this Update are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company does not expect to early adopt this ASU. The Company is currently assessing the potential impact that the adoption of this ASU will have on its condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
Loss Per Share	Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 705,976 and 226,434 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2023 and 2022, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2023 2022 Stock options 234,213 184,936 Warrants 465,888 35,623 Preferred stock 5,875 5,875 Total 705,976 226,434
Consolidation of Variable Interest Entities	Consolidation of Variable Interest Entities. We evaluate any entity in which we are involved to determine if the entity is a VIE and if so, whether we hold a variable interest and are the primary beneficiary. We consolidate VIEs that are subject to assessment when we are deemed to be the primary beneficiary of the VIE. The process for determining whether we are the primary beneficiary of the VIE is to conclude whether we are a party to the VIE holding a variable interest that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE, and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. ​ We have determined that we hold a variable interest in the Joint Venture, have the power to make significant operational decisions on behalf of the VIE and also have the obligation to absorb the majority of the losses from the VIE. As such we have also determined that we are the primary beneficiary of the VIE. The following table presents information about the carrying value of the assets and liabilities of the Joint Venture which we consolidate and which are included on our condensed consolidated balance sheets. Intercompany balances are eliminated in consolidation and not reflected in the following table. ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 219 ​ $ 335 Total assets ​ $ 219 ​ $ 335 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 17 ​ $ 50 Total liabilities ​ $ 17 ​ $ 50 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 65 Equity attributable to Precipio, Inc. ​ $ 127 ​ $ 127 ​

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of outstanding securities not included in the computation of diluted net loss per share	The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2023 2022 Stock options 234,213 184,936 Warrants 465,888 35,623 Preferred stock 5,875 5,875 Total 705,976 226,434
Schedule of Variable Interest Entities	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 219 ​ $ 335 Total assets ​ $ 219 ​ $ 335 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 17 ​ $ 50 Total liabilities ​ $ 17 ​ $ 50 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 65 Equity attributable to Precipio, Inc. ​ $ 127 ​ $ 127 ​

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2023
LONG-TERM DEBT [Abstract]
Schedule of debt	Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ September 30, 2023 December 31, 2022 Connecticut Department of Economic and Community Development (DECD) ​ $ 154 ​ $ 176 DECD debt issuance costs ​ (13) ​ (15) Financed insurance loan ​ 306 ​ 228 Total long-term debt ​ 447 ​ 389 Current portion of long-term debt ​ (334) ​ (255) Long-term debt, net of current maturities ​ $ 113 ​ $ 134

ACCRUED EXPENSES OTHER CURREN_2

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Accrued expenses	Accrued expenses at September 30, 2023 and December 31, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Accrued expenses ​ $ 1,212 ​ $ 983 Accrued compensation ​ 846 ​ 491 Accrued franchise, property and sales and use taxes ​ ​ 136 ​ ​ 91 Accrued interest ​ 19 ​ 19 ​ ​ $ 2,213 ​ $ 1,584

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2023
LEASES [Abstract]
Summary of balance sheet presentation of our operating and finance leases	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Condensed Consolidated Balance Sheet ​ September 30, 2023 ​ December 31, 2022 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 668 ​ $ 763 Finance lease right-of-use assets, net (1) ​ ​ 194 ​ ​ 257 Total lease assets ​ $ 862 ​ $ 1,020 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 222 ​ $ 199 Current maturities of finance lease liabilities ​ ​ 143 ​ ​ 162 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 459 ​ ​ 574 Finance lease liabilities, less current maturities ​ ​ 25 ​ ​ 68 Total lease liabilities ​ $ 849 ​ $ 1,003 (1) As of September 30, 2023 and December 31, 2022, finance lease right-of-use assets included $3 thousand and $13 thousand, respectively, of assets related to finance leases associated with the HSRR program.
Summary of estimated future minimum lease payments for operating leases	As of September 30, 2023, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ September 30, ​ ​ September 30, ​ ​ September 30, ​ ​ ​ 2023 ​ ​ 2023 ​ ​ 2023 2023 (remaining) ​ $ 68 ​ $ 22 ​ $ 90 2024 ​ 258 ​ 80 ​ 338 2025 ​ 224 ​ 65 ​ 289 2026 ​ 214 ​ ​ 26 ​ 240 Total lease obligations ​ 764 ​ 193 ​ 957 Less: Amount representing interest ​ (83) ​ (25) ​ (108) Present value of net minimum lease obligations ​ 681 ​ 168 ​ 849 Less, current portion ​ (222) ​ (143) ​ (365) Long term portion ​ $ 459 ​ $ 25 ​ $ 484
Summary of estimated future minimum lease payments for finance leases	As of September 30, 2023, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ September 30, ​ ​ September 30, ​ ​ September 30, ​ ​ ​ 2023 ​ ​ 2023 ​ ​ 2023 2023 (remaining) ​ $ 68 ​ $ 22 ​ $ 90 2024 ​ 258 ​ 80 ​ 338 2025 ​ 224 ​ 65 ​ 289 2026 ​ 214 ​ ​ 26 ​ 240 Total lease obligations ​ 764 ​ 193 ​ 957 Less: Amount representing interest ​ (83) ​ (25) ​ (108) Present value of net minimum lease obligations ​ 681 ​ 168 ​ 849 Less, current portion ​ (222) ​ (143) ​ (365) Long term portion ​ $ 459 ​ $ 25 ​ $ 484
Schedule of other information	​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2023 ​ 2022 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 3.0 ​ 3.7 Finance leases 2.3 ​ 2.8 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 10.54% ​ 10.31%

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2023
STOCKHOLDERS' EQUITY [Abstract]
Schedule of stockholders' equity, including warrants and rights	The following represents a summary of the warrants outstanding as of September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Underlying Exercise ​ ​ Issue Year ​ Expiration ​ Shares ​ Price Warrants ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) ​ 2018 ​ November 2023 ​ 3,789 ​ $ 108.00 (2) ​ 2018 ​ December 2023 ​ 2,564 ​ $ 108.00 (3) ​ 2019 ​ April 2024 ​ 7,374 ​ $ 108.00 (4) ​ 2019 ​ May 2024 ​ 7,717 ​ $ 191.20 (5) ​ 2023 ​ None ​ 15,972 ​ $ 0.02 (6) ​ 2023 ​ December 2028 ​ 444,444 ​ $ 12.60 ​ 481,860 ​ (1)(2)(3) (4) (5)(6) ​

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
	Sep. 30, 2023
FAIR VALUE [Abstract]
Schedule of Changes in Fair Value of Liability	​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ Bridge Note ​ Warrant Liabilities ​ Beginning balance at July 1 $ 87 ​ Total gains: ​ Revaluation recognized in earnings ​ (59) ​ Balance at September 30 $ 28 ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 ​ Bridge Note ​ Warrant Liabilities Beginning balance at January 1 $ 606 Total gains: Revaluation recognized in earnings ​ (578) Balance at September 30 $ 28 ​

EQUITY INCENTIVE PLAN (Tables)

EQUITY INCENTIVE PLAN (Tables)	9 Months Ended
	Sep. 30, 2023
EQUITY INCENTIVE PLAN [Abstract]
Summary of stock option activity	The following table summarizes stock option activity under our plans during the nine months ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2023 184,067 ​ $ 56.75 Granted 58,530 ​ 12.12 Forfeited (8,384) ​ 24.12 Outstanding at September 30, 2023 234,213 ​ $ 46.77 Exercisable at September 30, 2023 141,908 ​ $ 57.93

SALES SERVICE REVENUE, NET AN_2

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2023
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Schedule of Net Revenues	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, (dollars in thousands) ​ Diagnostic Testing ​ 2023 2022 Medicaid ​ $ 10 ​ $ 12 Medicare ​ 1,691 ​ 936 Self-pay ​ 39 ​ 109 Third party payers ​ 1,998 ​ 1,003 Service revenue, net ​ $ 3,738 ​ $ 2,060 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, (dollars in thousands) ​ Diagnostic Testing ​ 2023 2022 Medicaid ​ $ 22 ​ $ 39 Medicare ​ 3,736 ​ 2,986 Self-pay ​ 155 ​ 206 Third party payers ​ 4,661 ​ 3,060 Service revenue, net ​ $ 8,574 ​ $ 6,291 ​
Schedule of Gross to Net Sales Adjustments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 10 ​ $ 12 ​ $ — ​ $ — ​ $ 10 ​ $ 12 Medicare ​ 1,693 ​ 936 ​ (2) ​ — ​ 1,691 ​ 936 Self-pay ​ 39 ​ 109 ​ — ​ — ​ 39 ​ 109 Third party payers ​ 6,956 ​ 3,486 ​ (4,958) ​ (2,483) ​ 1,998 ​ 1,003 ​ ​ 8,698 ​ 4,543 ​ (4,960) ​ (2,483) ​ 3,738 ​ 2,060 Other ​ 831 ​ 235 ​ — ​ — ​ 831 ​ 235 ​ ​ $ 9,529 ​ $ 4,778 ​ $ (4,960) ​ $ (2,483) ​ $ 4,569 ​ $ 2,295 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 22 ​ $ 39 ​ $ — ​ $ — ​ $ 22 ​ $ 39 Medicare ​ 3,738 ​ 2,986 ​ (2) ​ — ​ 3,736 ​ 2,986 Self-pay ​ 155 ​ 206 ​ — ​ — ​ 155 ​ 206 Third party payers ​ 16,233 ​ 10,664 ​ (11,572) ​ (7,604) ​ 4,661 ​ 3,060 ​ ​ 20,148 ​ 13,895 ​ (11,574) ​ (7,604) ​ 8,574 ​ 6,291 Other ​ 2,469 ​ 977 ​ — ​ — ​ 2,469 ​ 977 ​ ​ $ 22,617 ​ $ 14,872 ​ $ (11,574) ​ $ (7,604) ​ $ 11,043 ​ $ 7,268
Schedule of Reported Revenues Net of Collection Allowance	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended September 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 10 ​ $ 12 ​ $ (4) ​ $ (6) ​ $ 6 ​ $ 6 Medicare ​ 1,691 ​ 936 ​ (20) ​ (24) ​ 1,671 ​ 912 Self-pay ​ 39 ​ 109 ​ (3) ​ — ​ 36 ​ 109 Third party payers ​ 1,998 ​ 1,003 ​ (24) ​ (50) ​ 1,974 ​ 953 ​ ​ 3,738 ​ 2,060 ​ (51) ​ (80) ​ 3,687 ​ 1,980 Other ​ 831 ​ 235 ​ — ​ — ​ 831 ​ 235 ​ ​ $ 4,569 ​ $ 2,295 ​ $ (51) ​ $ (80) ​ $ 4,518 ​ $ 2,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Nine Months Ended September 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2023 2022 2023 2022 2023 2022 Medicaid ​ $ 22 ​ $ 39 ​ $ (10) ​ $ (19) ​ $ 12 ​ $ 20 Medicare ​ 3,736 ​ 2,986 ​ (43) ​ (75) ​ 3,693 ​ 2,911 Self-pay ​ 155 ​ 206 ​ (15) ​ — ​ 140 ​ 206 Third party payers ​ 4,661 ​ 3,060 ​ (107) ​ (153) ​ 4,554 ​ 2,907 ​ ​ 8,574 ​ 6,291 ​ (175) ​ (247) ​ 8,399 ​ 6,044 Other ​ 2,469 ​ 977 ​ — ​ — ​ 2,469 ​ 977 ​ ​ $ 11,043 ​ $ 7,268 ​ $ (175) ​ $ (247) ​ $ 10,868 ​ $ 7,021 ​
Schedule of Receivables	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) September 30, 2023 December 31, 2022 Medicaid ​ $ 26 ​ $ 34 Medicare ​ 1,671 ​ 1,124 Self-pay ​ 258 ​ 291 Third party payers ​ 1,495 ​ 1,888 Contract diagnostic services and other ​ 562 ​ 53 ​ ​ $ 4,012 ​ $ 3,390 Less allowance for doubtful accounts ​ (2,529) ​ (2,354) Accounts receivable, net ​ $ 1,483 ​ $ 1,036
Schedule of Allowance for Doubtful Accounts	The following table presents the roll-forward of the allowance for doubtful accounts for the nine months ended September 30, 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Doubtful (dollars in thousands) ​ ​ ​ ​ Accounts Balance, January 1, 2023 ​ ​ $ (2,354) Collection Allowance: ​ ​ Medicaid ​ $ (10) ​ Medicare ​ (43) ​ Self-pay ​ ​ (15) ​ ​ ​ Third party payers ​ (107) ​ ​ ​ (175) ​ Bad debt expense ​ $ — ​ Total charges ​ ​ (175) Balance, September 30, 2023 ​ ​ $ (2,529)
Schedule of Customer Revenue and Accounts Receivable Concentrations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Three Months Ended ​ ​ Nine Months Ended ​ ​ ​ ​ ​ ​ September 30, ​ ​ September 30, ​ ​ September 30, ​ December 31, ​ ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ 13 % * ​ ​ 14 % * ​ ​ 25 % * ​ Customer B ​ 12 % * ​ ​ * ​ * ​ ​ 11 % * ​ Customer C ​ * ​ * ​ ​ * ​ * ​ ​ * ​ 12 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

BUSINESS DESCRIPTION (Narrative

BUSINESS DESCRIPTION (Narrative) (Details) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended		31 Months Ended
	Sep. 21, 2023	Jun. 08, 2023 USD ($) shares	Apr. 14, 2023 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Nov. 10, 2023 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares	Apr. 02, 2021 $ / shares	Apr. 13, 2020 USD ($)
Business Acquisition [Line Items]
Net loss				$ 6,800		$ 6,800
Net cash used in operating activities						(3,673)	$ (6,221)
Accumulated deficit				(99,075)		(99,075)			$ (92,297)
Working deficiency				$ 1,100		1,100
Proceeds from issuance of common stock						$ 2,245	129
Reverse stock split	0.05
Common stock, par value | $ / shares				$ 0.01		$ 0.01			$ 0.01
AGP 2023 Sales Agreement [Member]
Business Acquisition [Line Items]
Proceeds from issuance of common stock				$ 1		$ 1
Aggregate authorized offering price			$ 5,800
Sale of common stock | shares			25	25		25
Amount available for future sale of shares pursuant to the sales agreement			$ 3,800	$ 3,800		$ 3,800
AGP 2023 Sales Agreement [Member] | Maximum [Member]
Business Acquisition [Line Items]
Proceeds from issuance of common stock			$ 1
Securities purchase agreement
Business Acquisition [Line Items]
Proceeds from issuance of common stock		$ 2,000
Sale of common stock | shares		206,250
Payments of stock issuance costs		$ 200
AGP | At The Market Offering Agreement
Business Acquisition [Line Items]
Proceeds from issuance of common stock				$ 0	$ 100	$ 500	$ 100	$ 15,600
Common stock, par value | $ / shares										$ 0.01
Aggregate authorized offering price											$ 50,000
Sale of common stock | shares				0	4,251	30,827	4,251	260,128
Payments of stock issuance costs								$ 500

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Securities not included in the computation of diluted net loss per share	705,976	226,434

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	705,976	226,434
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	234,213	184,936
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	465,888	35,623
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	5,875	5,875

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (VIE) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Assets:
Accounts receivable, net	$ 1,483		$ 1,036
Total assets	19,053		21,504
Liabilities:
Accrued expenses	2,213		1,584
Total liabilities	6,051		5,137
Equity attributable to Precipio, Inc.	13,002	$ 14,091	16,367	$ 18,254	$ 20,565	$ 24,604
Variable Interest Entity, Primary Beneficiary [Member]
Assets:
Accounts receivable, net	219		335
Total assets	219		335
Liabilities:
Accrued expenses	17		50
Total liabilities	17		50
Noncontrolling Interest in Joint Venture	65		65
Equity attributable to Precipio, Inc.	$ 127		$ 127

LONG-TERM DEBT (Schedule of Deb

LONG-TERM DEBT (Schedule of Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total long-term debt	$ 447	$ 389
Current portion of long-term debt	(334)	(255)
Long-term debt, net of current maturities	113	134
Connecticut Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Total long-term debt	154	176
Debt issuance cost	(13)	(15)
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Total long-term debt	306	228
Current portion of long-term debt	$ (300)	$ (200)

LONG-TERM DEBT (Narrative) (Det

LONG-TERM DEBT (Narrative) (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jan. 08, 2018	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jul. 31, 2023	Dec. 31, 2022	Jul. 31, 2022
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		$ 334,000		$ 334,000			$ 255,000
Connecticut Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Debt instrument, term	10 years
Debt instrument, maturity date	Dec. 31, 2027			May 31, 2028
Interest rate (as a percent)	3.25%
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		300,000		$ 300,000			$ 200,000
Interest rate (as a percent)						9.99%		5.99%
Debt instrument, face amount						$ 400,000		$ 400,000
Term loan | Connecticut Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Proceeds from long-term debt	$ 300,000
Amortization of debt issuance cost				$ 2,000	$ 3,000
Term loan | Connecticut Department of Economic and Community Development (DECD) | Maximum [Member]
Debt Instrument [Line Items]
Amortization of debt issuance cost		$ 1,000	$ 1,000

ACCRUED EXPENSES OTHER CURREN_3

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Accrued expenses	$ 1,212	$ 983
Accrued compensation	846	491
Accrued franchise, property and sales and use taxes	136	91
Accrued interest	19	19
Accrued expenses	$ 2,213	$ 1,584

ACCRUED EXPENSES OTHER CURREN_4

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Reduction in certain accrued expense and accounts payable	$ 0	$ 3,000	$ 0	$ 4,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Millions	Feb. 06, 2017	Sep. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Other Commitment		$ 0.7	$ 1.3
CPA Global
Loss Contingencies [Line Items]
Loss contingency, damages sought	$ 0.2
CPA Global | Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency accrual		$ 0.1	$ 0.1

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) item	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating leases			$ 200	$ 100
Operating lease right-of-use assets obtained in exchange for operating lease obligations			58	92
Finance lease ROU assets			$ 63	99
Minimum [Member]
Lessee, Lease, Description [Line Items]
Facility leases | item			1
Renewal term	1 year		1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Renewal term	5 years		5 years
HemeScreen Reagent Rental [Member]
Lessee, Lease, Description [Line Items]
Finance lease ROU assets	$ 0	$ 0	$ 0	$ 0
Net investment in leased assets	$ 100		$ 100		$ 100

LEASES - Operating and Financin

LEASES - Operating and Financing leases (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Balance sheet presentation of our operating and financing leases
Operating lease right-of-use assets, net	$ 668	$ 763
Finance lease right-of-use assets, net	194	257
Total lease assets	862	1,020
Current maturities of operating lease liabilities	222	199
Current maturities of finance lease liabilities	143	162
Operating lease liabilities, less current maturities	459	574
Finance lease liabilities, less current maturities	25	68
Total lease liabilities	849	1,003
HemeScreen Reagent Rental [Member]
Balance sheet presentation of our operating and financing leases
Finance lease right-of-use assets, net	$ 3	$ 13

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Operating leases, estimated future minimum lease payments
2023 (remaining)	$ 68
2024	258
2025	224
2026	214
Total lease obligations	764
Less: Amount representing interest	(83)
Present value of net minimum lease obligations	681
Less, current portion	(222)	$ (199)
Long term portion	459	574
Finance leases, estimated future minimum lease payments
2023 (remaining)	22
2024	80
2025	65
2026	26
Total lease obligations	193
Less: Amount representing interest	(25)
Present value of net minimum lease obligations	168
Less, current portion	(143)	(162)
Long term portion	25	68
2023 (remaining)	90
2024	338
2025	289
2026	240
Total lease obligations	957
Less: Amount representing interest	(108)
Total lease liabilities	849	$ 1,003
Less, current portion	(365)
Long term portion	$ 484

LEASES - Other Information (Det

LEASES - Other Information (Details)	Sep. 30, 2023	Dec. 31, 2022
LEASES [Abstract]
Operating leases (in years)	3 years	3 years 8 months 12 days
Finance leases (in years)	2 years 3 months 18 days	2 years 9 months 18 days
Operating leases discount rate	8%	8%
Finance leases discount rate	10.54%	10.31%

LEASES - Operating and Financ_2

LEASES - Operating and Financing Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 0.1	$ 0.1	$ 0.2	$ 0.2
Maximum [Member]
Lessee, Lease, Description [Line Items]
Short-term lease costs	0.1	0.1	0.1	0.1
Finance leases, amortization expense and interest	$ 0.1	$ 0.1	$ 0.1	$ 0.1

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock, 2018 Purchase Agreement and LP Purchase Agreement) (Details) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
		Sep. 21, 2023	Sep. 30, 2023 $ / shares shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Dec. 31, 2022 shares	Dec. 20, 2018 shares	Dec. 19, 2018 shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			150,000,000		150,000,000		150,000,000	250,000,000	150,000,000
Proceeds from exercise of warrants | $						$ 11
Reverse stock split		0.05
Shares issued (in shares)			1,380,555		1,380,555		1,141,013
Common stock, shares outstanding (in shares)			1,380,555		1,380,555		1,141,013
Issuance of common stock, net of issuance costs | $					$ 2,245	$ 129
Common Stock [Member]
Class of Stock [Line Items]
Proceeds upon issuance of common stock from exercise of warrants (in shares)	[1]			1,327		1,340
Shares issued (in shares)	[1]				30,852	4,251
Restricted shares issued (in shares)	[1]		2,492		2,492
Common Stock [Member]
Class of Stock [Line Items]
Proceeds upon issuance of common stock from exercise of warrants (in shares)			0	1,327	0	1,340
Warrant exercises in period				1,327		1,340
Preferred Class B
Class of Stock [Line Items]
Conversion price (in dollars per share) | $ / shares			$ 8		$ 8
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Proceeds from exercise of warrants | $				$ 11		$ 11
[1] The common stock and additional paid-in capital for all periods presented reflect the one-for- twenty reverse stock split, which was effected on September 21, 2023.

STOCKHOLDERS' EQUITY (At The Ma

STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended		31 Months Ended
	Apr. 14, 2023	Apr. 02, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Nov. 10, 2023	Dec. 31, 2022	Apr. 13, 2020
Class of Stock [Line Items]
Common stock, par value			$ 0.01		$ 0.01			$ 0.01
Proceeds from issuance of common stock					$ 2,245	$ 129
AGP 2023 Sales Agreement [Member]
Class of Stock [Line Items]
Aggregate authorized offering price	$ 5,800
Percentage of cash fee	3%
Proceeds from issuance of common stock			$ 1		$ 1
Shares issued (in shares)	25		25		25
Amount available for future sale of shares pursuant to the sales agreement	$ 3,800		$ 3,800		$ 3,800
AGP | At The Market Offering Agreement
Class of Stock [Line Items]
Common stock, par value		$ 0.01
Aggregate sales proceeds of common stock		$ 22,000
Payments of Stock Issuance Costs							$ 500
Aggregate authorized offering price									$ 50,000
Percentage of cash fee		3%
Proceeds from issuance of common stock			$ 0	$ 100	$ 500	$ 100	$ 15,600
Shares issued (in shares)			0	4,251	30,827	4,251	260,128

STOCKHOLDERS' EQUITY (Registere

STOCKHOLDERS' EQUITY (Registered Direct Offering) (Details)			1 Months Ended	9 Months Ended
	Jun. 08, 2023 USD ($) $ / shares Y shares	Jun. 07, 2023 USD ($)	Jun. 30, 2023 $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 $ / shares
Class of Stock [Line Items]
Common stock, par value				$ 0.01		$ 0.01
Class of warrant, number of securities called by warrants | shares				481,860
Proceeds from issuance of common stock | $				$ 2,245,000	$ 129,000
Pre-Funded Warrants
Class of Stock [Line Items]
Number of warrants issued | shares			15,972
Class of warrant, number of securities called by warrants | shares			15,972	15,972
Share price (in dollars per share)			$ 8.98
Exercise price (in dollars per share)			$ 0.02	$ 0.02
RDO Common Warrants
Class of Stock [Line Items]
Number of warrants issued | shares			444,444
Class of warrant, number of securities called by warrants | shares			444,444	444,444
Period from issuance after which the warrants become exercisable.			6 months
Exercise price (in dollars per share)			$ 12.60	$ 12.60
Registered Direct Offering [Member]
Class of Stock [Line Items]
Stock reserved for future issuance | shares	206,250
Common stock, par value	$ 0.01
Share price (in dollars per share)	$ 9
Threshold beneficial ownership percentage of warrants with its affiliates	4.99%
Threshold beneficial ownership percentage of warrants at the election of the purchaser	9.99%
Threshold ownership percentage of warrants	19.99%
Notice period to alter beneficial ownership percentage	61 days
Gross proceeds | $	$ 2,000,000
Proceeds from issuance of common stock | $	$ 1,800,000
Lock-in period	90 days
Resale registration period	30 days
Cash fee paid | $		$ 140,000
Sale lock in period	90 days
Variable rate transaction lock in period	180 days
Amount available for future sale of shares pursuant to the sales agreement | $				$ 3,800,000
Registered Direct Offering [Member] | Pre-Funded Warrants
Class of Stock [Line Items]
Class of warrant, number of securities called by warrants | shares	15,972			0
Share price (in dollars per share)	$ 8.98
Exercise price (in dollars per share)	$ 0.02
Registered Direct Offering [Member] | RDO Common Warrants
Class of Stock [Line Items]
Class of warrant, number of securities called by warrants | shares	444,444
Period from issuance after which the warrants become exercisable.	6 months
Exercise price (in dollars per share)	$ 12.60
Fair value of warrants issued | $	$ 3,500,000
Gross proceeds | $	$ 1,300,000
Registered Direct Offering [Member] | Measurement Input, Expected Term [Member] | RDO Common Warrants
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input | Y	5
Registered Direct Offering [Member] | Measurement Input, Risk Free Interest Rate [Member] | RDO Common Warrants
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input | $	0.0389
Registered Direct Offering [Member] | Measurement Input, Price Volatility [Member] | RDO Common Warrants
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input | $	1.43
Registered Direct Offering [Member] | Measurement Input, Share Price [Member] | RDO Common Warrants
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input	9

STOCKHOLDERS' EQUITY (Preferred

STOCKHOLDERS' EQUITY (Preferred Stock) (Details) - shares	Sep. 30, 2023	Dec. 31, 2022
STOCKHOLDERS' EQUITY [Abstract]
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000

STOCKHOLDERS' EQUITY (Series B

STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 28, 2017
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000		15,000,000		15,000,000
Preferred stock, shares outstanding (in shares)	47		47		47
Preferred stock, shares issued (in shares)	47		47		47
Preferred Class B
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)						$ 0.01
Conversion price (in dollars per share)	$ 8		$ 8
Number of shares converted (in shares)	0	0	0	0
Preferred stock, shares authorized (in shares)	6,900		6,900		6,900	6,900
Preferred stock, shares outstanding (in shares)	47		47		47
Preferred stock, shares issued (in shares)	6,900		6,900		6,900
Preferred stock, dividend rate (percentage)			0%
Preferred Stock, Liquidation Preference Per Share	$ 1,000		$ 1,000			$ 1,000
Number of common shares issuable upon conversion of preferred stock.	5,875		5,875

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Class of Stock [Line Items]
Underlying shares (in shares)	481,860		481,860
Warrants expired	5,593		13,012
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Intrinsic value of warrants exercised in period		$ 20		$ 20
Warrants Not Assumed In Merger, Expiring November 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	3,789		3,789
Exercise price (in dollars per share)	$ 108		$ 108
Warrants Not Assumed In Merger, Expiring December 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	2,564		2,564
Exercise price (in dollars per share)	$ 108		$ 108
Warrants Not Assumed In Merger, Expiring April 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	7,374		7,374
Exercise price (in dollars per share)	$ 108		$ 108
Warrants Not Assumed In Merger, Expiring May 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	7,717		7,717
Exercise price (in dollars per share)	$ 191.20		$ 191.20
Pre-Funded Warrants
Class of Stock [Line Items]
Underlying shares (in shares)	15,972		15,972		15,972
Exercise price (in dollars per share)	$ 0.02		$ 0.02		$ 0.02
RDO Common Warrants
Class of Stock [Line Items]
Underlying shares (in shares)	444,444		444,444		444,444
Exercise price (in dollars per share)	$ 12.60		$ 12.60		$ 12.60

STOCKHOLDERS' EQUITY (Warrants)

STOCKHOLDERS' EQUITY (Warrants) (Details) - $ / shares	1 Months Ended
	Jun. 30, 2023	Sep. 30, 2023
Class of Warrant or Right [Line Items]
Class of warrant, number of securities called by warrants		481,860
Pre-Funded Warrants
Class of Warrant or Right [Line Items]
Number of warrants issued	15,972
Class of warrant, number of securities called by warrants	15,972	15,972
Share price (in dollars per share)	$ 8.98
Exercise price (in dollars per share)	$ 0.02	$ 0.02
RDO Common Warrants
Class of Warrant or Right [Line Items]
Number of warrants issued	444,444
Class of warrant, number of securities called by warrants	444,444	444,444
Exercise price (in dollars per share)	$ 12.60	$ 12.60
Period from issuance after which the warrants become exercisable.	6 months

FAIR VALUE (Narratives) (Detail

FAIR VALUE (Narratives) (Details) - Bridge Note Warrant Liabilities [Member]	Sep. 30, 2023 Y	Dec. 31, 2022 Y
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.69	0.69
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.0553	0.0442
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.25	0.3
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.85	0.77
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.0555	0.0476
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.62	1.4

FAIR VALUE (Schedule of Changes

FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total losses:
Revaluation recognized in earnings		$ (59)		$ (578)
Warrant Liabilities [Member] | Maximum [Member]
Total losses:
Revaluation recognized in earnings	$ 1		$ 1
Bridge Note Warrant Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		87		606
Total losses:
Revaluation recognized in earnings		(59)		(578)
Balance at end of period		$ 28		$ 28

EQUITY INCENTIVE PLAN (Narrativ

EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 400	$ 700	$ 1,200	$ 3,400
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			58,530
Granted (in dollars per share)			$ 12.12
Forfeited (in shares)			(8,384)
Forfeited (in dollars per share)			$ 24.12
Weighted average grant date fair value (in dollars per share)			$ 11.60
Risk free interest rate, minimum			3.66%
Risk free interest rate, maximum			4.05%
Term			6 years
Stock options, expected to vest, outstanding (in shares)	210,096		210,096
Stock options, expected to vest, outstanding, aggregate intrinsic value	$ 0		$ 0
Stock options, expected to vest remaining contractual term			7 years 9 months 18 days
Unrecognized compensation expense related to unvested stock awards	$ 2,500		$ 2,500
Unvested stock options, unrecognized compensation expense weighted average recognition period (in years)			2 years 1 month 6 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expected to vest, outstanding (in shares)	2,492		2,492
Restricted stock granted	2,492	0	2,492	0
Awards outstanding	0		0
Award weight average grant date fair value	$ 5.90		$ 5.90
Stock-based compensation	$ 16		$ 16
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate			146%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate			162%
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period			4 years
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	249,693		249,693
Shares available for grant	12,926		12,926
Percentage of annual increase in number of shares authorized for grant			5%
Number of additional shares authorized			57,051
Equity Incentive Plan 2017 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Plan expiration date			Jun. 05, 2027

EQUITY INCENTIVE PLAN (Summary

EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Options
Outstanding at beginning of period (in shares) | shares	184,067
Granted (in shares) | shares	58,530
Forfeited (in shares) | shares	(8,384)
Outstanding at end of period (in shares) | shares	234,213
Exercisable at end of period (in shares) | shares	141,908
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 56.75
Granted (in dollars per share) | $ / shares	12.12
Forfeited (in dollars per share) | $ / shares	24.12
Outstanding at end of period (in dollars per share) | $ / shares	46.77
Exercisable at end of period (in dollars per share) | $ / shares	$ 57.93

SALES SERVICE REVENUE, NET AN_3

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) segment	Dec. 31, 2022 USD ($)
Concentration Risk [Line Items]
Number of segments | segment	1
Deferred revenue	$ 29	$ 119
Maximum [Member]
Concentration Risk [Line Items]
Deferred revenue	$ 100

SALES SERVICE REVENUE, NET AN_4

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,569	$ 2,295	$ 11,043	$ 7,268
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,738	2,060	8,574	6,291
Medicaid [Member] | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	10	12	22	39
Medicaid [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	10	12	22	39
Medicare [Member] | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,691	936	3,736	2,986
Medicare [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,691	936	3,736	2,986
Self-Pay | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	39	109	155	206
Self-Pay | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	39	109	155	206
Third-Party Payor [Member] | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,998	1,003	4,661	3,060
Third-Party Payor [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,998	1,003	4,661	3,060
Services Revenue, Net [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 3,738	$ 2,060	$ 8,574	$ 6,291

SALES SERVICE REVENUE, NET AN_5

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Gross revenue	$ 9,529	$ 4,778	$ 22,617	$ 14,872
Contractual allowance and adjustments	(4,960)	(2,483)	(11,574)	(7,604)
Service revenue, net	4,569	2,295	11,043	7,268
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	8,698	4,543	20,148	13,895
Contractual allowance and adjustments	(4,960)	(2,483)	(11,574)	(7,604)
Service revenue, net	3,738	2,060	8,574	6,291
Service revenue, net [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	10	12	22	39
Service revenue, net	10	12	22	39
Service revenue, net [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	1,693	936	3,738	2,986
Contractual allowance and adjustments	(2)		(2)
Service revenue, net	1,691	936	3,736	2,986
Service revenue, net [Member] | Self-Pay
Disaggregation of Revenue [Line Items]
Gross revenue	39	109	155	206
Service revenue, net	39	109	155	206
Service revenue, net [Member] | Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	6,956	3,486	16,233	10,664
Contractual allowance and adjustments	(4,958)	(2,483)	(11,572)	(7,604)
Service revenue, net	1,998	1,003	4,661	3,060
Other [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	831	235	2,469	977
Service revenue, net	$ 831	$ 235	$ 2,469	$ 977

SALES SERVICE REVENUE, NET AN_6

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,569	$ 2,295	$ 11,043	$ 7,268
Adjustment for allowance for doubtful accounts	(51)	(80)	(175)	(247)
Net sales	4,518	2,215	10,868	7,021
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Adjustment for allowance for doubtful accounts			(10)
Medicare [Member]
Disaggregation of Revenue [Line Items]
Adjustment for allowance for doubtful accounts			(43)
Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Adjustment for allowance for doubtful accounts			(107)
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,738	2,060	8,574	6,291
Adjustment for allowance for doubtful accounts	(51)	(80)	(175)	(247)
Net sales	3,687	1,980	8,399	6,044
Service revenue, net [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	10	12	22	39
Adjustment for allowance for doubtful accounts	(4)	(6)	(10)	(19)
Net sales	6	6	12	20
Service revenue, net [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,691	936	3,736	2,986
Adjustment for allowance for doubtful accounts	(20)	(24)	(43)	(75)
Net sales	1,671	912	3,693	2,911
Service revenue, net [Member] | Self-Pay
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	39	109	155	206
Adjustment for allowance for doubtful accounts	(3)		(15)
Net sales	36	109	140	206
Service revenue, net [Member] | Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,998	1,003	4,661	3,060
Adjustment for allowance for doubtful accounts	(24)	(50)	(107)	(153)
Net sales	1,974	953	4,554	2,907
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	831	235	2,469	977
Net sales	$ 831	$ 235	$ 2,469	$ 977

SALES SERVICE REVENUE, NET AN_7

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable, gross	$ 4,012	$ 3,390
Less allowance for doubtful accounts	(2,529)	(2,354)
Accounts receivable, net	1,483	1,036
Medicaid [Member]
Accounts receivable, gross	26	34
Medicare [Member]
Accounts receivable, gross	1,671	1,124
Self-Pay
Accounts receivable, gross	258	291
Third-Party Payor [Member]
Accounts receivable, gross	1,495	1,888
Contract Diagnostic Services and Other [Member]
Accounts receivable, gross	$ 562	$ 53

SALES SERVICE REVENUE, NET AN_8

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Allowance for doubtful accounts, Beginning balance			$ (2,354)
Adjustment for allowance for doubtful accounts	$ (51)	$ (80)	(175)	$ (247)
Total charges			175
Allowance for doubtful accounts, Ending balance	$ (2,529)		(2,529)
Medicaid [Member]
Adjustment for allowance for doubtful accounts			(10)
Medicare [Member]
Adjustment for allowance for doubtful accounts			(43)
Third-Party Payor [Member]
Adjustment for allowance for doubtful accounts			(107)
Self-Pay [Member]
Adjustment for allowance for doubtful accounts			$ (15)

SALES SERVICE REVENUE, NET AN_9

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details) - Customer Concentration Risk [Member]	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13%	14%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	12%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		25%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		11%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			12%